Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesise that nebulised hypertonic saline (6%) will increase the volume of sputum expectorated over a 24 hour period compared to nebulised isotonic saline (0.9%) in patients with mild to severe stable bronchiectasis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiectasis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bronchiectasis Hypertonic saline

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hypertonic saline

Hypertonic saline (6%) nebulised twice a day for 4 weeks.

(Randomised crossover trial)

Intervention Type OTHER

Isotonic saline

Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non CF Bronchiectasis
* 18-80 years
* FEV1 less than 90%
* Chronic sputum production
* Clinical stable

Exclusion Criteria

* Intolerance to HTS
* Use of HTSaline or antibiotics 14 days prior to study
* Clinically unstable
* Smokers

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Belfast Health and Social Care Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Belfast HSCT

Belfast, Northern Ireland, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Judy Bradley, PHD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09023JB-OPMS

Identifier Type: -

Identifier Source: org_study_id